Close menu

Two months after the start of “ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.


Lyon, February 2, 2023 – Advanced BioDesign (ABD), a French biotech company specialising in the development of a new family of targeted oncological therapies, announced today that it has signed an agreement with Xerys Invest, its shareholder since 2013, for a €14.3 million capital injection. This significant financial support is in addition to the €20 million already raised from Xerys Invest.


This additional funding for ABD comes two months after the launch of its “ODYSSEY” Phase I (First-In-Human) clinical trial targeting acute myeloid leukaemia (AML), one of the most common and severe leukaemias in adults over 60 years of age, with a 5-year survival rate of less than 20%. The first patient recruitments have been underway since November 2022 in three investigation centres (APHM in Marseille, HCL in Lyon and Saint-Louis Hospital in Paris).


Read the press release

More information